Highly Purified Vitamin B2 Presents a Promising Therapeutic Strategy for Sepsis and Septic Shock

Overview

Journal Infect Immun

Publisher American Society for Microbiology

Specialty Allergy & Immunology

Date 2004 Feb 24

PMID 14977995

Citations 18

Authors

Toshio Toyosawa

Mamoru Suzuki

Kohtarou Kodama

Seiichi Araki

Affiliations

Soon will be listed here.

Abstract

Highly purified vitamin B2 (riboflavin 5'-sodium phosphate; purity > 97%) treatment by intravenous infusion at doses above those used clinically to treat vitamin B2 deficiency showed therapeutic effects in mice not only in cases of endotoxin- and exotoxin-induced shock but also in cases of gram-negative and gram-positive bacterial infection even after the toxemia had already begun.

Citing Articles

Altered Urinary Metabolomics in Hereditary Angioedema.

Wang X, Zhi Y Metabolites. 2022; 12(11).

PMID: 36422280 PMC: 9696332. DOI: 10.3390/metabo12111140.

Riboflavin, a Potent Neuroprotective Vitamin: Focus on Flavivirus and Alphavirus Proteases.

Eberle R, Olivier D, Amaral M, Pacca C, Nogueira M, Arni R Microorganisms. 2022; 10(7).

PMID: 35889050 PMC: 9315535. DOI: 10.3390/microorganisms10071331.

Study on the Antipyretic and Anti-inflammatory Mechanism of Shuanghuanglian Oral Liquid Based on Gut Microbiota-Host Metabolism.

Gao Y, Liu L, Li C, Liang Y, Lv J, Yang L Front Pharmacol. 2022; 13:843877.

PMID: 35837285 PMC: 9273999. DOI: 10.3389/fphar.2022.843877.

Riboflavin Attenuates Influenza Virus Through Cytokine-Mediated Effects on the Diversity of the Gut Microbiota in MAIT Cell Deficiency Mice.

Li Y, Shi C, Zhang Y, Huang H, Jiang Y, Wang J Front Microbiol. 2022; 13:916580.

PMID: 35722312 PMC: 9204145. DOI: 10.3389/fmicb.2022.916580.

Riboflavin did not provide anti-inflammatory or antioxidant effects in an experimental model of sepsis.

Vale A, Nascimento D, Pineros A, Ferreira R, Santos J, Aragon D Braz J Med Biol Res. 2022; 55:e12107.

PMID: 35648977 PMC: 9150426. DOI: 10.1590/1414-431X2022e12107.

References

Dinarello C . Proinflammatory cytokines. Chest. 2000; 118(2):503-8. DOI: 10.1378/chest.118.2.503. View

Glauser M . Pathophysiologic basis of sepsis: considerations for future strategies of intervention. Crit Care Med. 2000; 28(9 Suppl):S4-8. DOI: 10.1097/00003246-200009001-00002. View

Angus D, Wax R . Epidemiology of sepsis: an update. Crit Care Med. 2001; 29(7 Suppl):S109-16. DOI: 10.1097/00003246-200107001-00035. View

Cohen J . The immunopathogenesis of sepsis. Nature. 2002; 420(6917):885-91. DOI: 10.1038/nature01326. View

Marshall J . Such stuff as dreams are made on: mediator-directed therapy in sepsis. Nat Rev Drug Discov. 2003; 2(5):391-405. DOI: 10.1038/nrd1084. View

. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 1992; 20(6):864-74. View

Bone R . Let's agree on terminology: definitions of sepsis. Crit Care Med. 1991; 19(7):973-6. DOI: 10.1097/00003246-199107000-00024. View

Bone R . The pathogenesis of sepsis. Ann Intern Med. 1991; 115(6):457-69. DOI: 10.7326/0003-4819-115-6-457. View

Osame S, Araki S, Kimura M . Effects of vitamin B2 on neutrophil functions in cattle. J Vet Med Sci. 1995; 57(3):493-5. DOI: 10.1292/jvms.57.493. View

10.

Barriere S, Lowry S . An overview of mortality risk prediction in sepsis. Crit Care Med. 1995; 23(2):376-93. DOI: 10.1097/00003246-199502000-00026. View

11.

Parrillo J . Pathogenetic mechanisms of septic shock. N Engl J Med. 1993; 328(20):1471-7. DOI: 10.1056/NEJM199305203282008. View

12.

Araki S, Suzuki M, Fujimoto M, Kimura M . Enhancement of resistance to bacterial infection in mice by vitamin B2. J Vet Med Sci. 1995; 57(4):599-602. DOI: 10.1292/jvms.57.599. View

13.

Endo S, Inada K, Nakae H, Arakawa N, Takakuwa T, Yamada Y . Nitrite/nitrate oxide (NOx) and cytokine levels in patients with septic shock. Res Commun Mol Pathol Pharmacol. 1996; 91(3):347-56. View

14.

Fein A, Bernard G, Criner G, Fletcher E, Good Jr J, Knaus W . Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127). Results of a randomized, double-blind, placebo-controlled trial. CP-0127 SIRS and Sepsis Study Group. JAMA. 1997; 277(6):482-7. View

15.

Bernard G, Wheeler A, Russell J, Schein R, Summer W, Steinberg K . The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. N Engl J Med. 1997; 336(13):912-8. DOI: 10.1056/NEJM199703273361303. View

16.

Dinarello C . Proinflammatory and anti-inflammatory cytokines as mediators in the pathogenesis of septic shock. Chest. 1997; 112(6 Suppl):321S-329S. DOI: 10.1378/chest.112.6_supplement.321s. View

17.

Dhainaut J, Tenaillon A, Hemmer M, Damas P, Le Tulzo Y, Radermacher P . Confirmatory platelet-activating factor receptor antagonist trial in patients with severe gram-negative bacterial sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. BN 52021 Sepsis Investigator Group. Crit Care Med. 1999; 26(12):1963-71. DOI: 10.1097/00003246-199812000-00021. View